Biotech News
Related news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-06-13 11:30 EST
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
MGTXMeiraGTx2026-07-07 11:30 EST
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
SGMOSangamo Therapeutics, Inc.2026-08-12 20:01 EST
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
ABEOAbeona Therapeutics2026-09-16 11:30 EST
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
SRPTSarepta Therapeutics2026-09-08 13:00 EST
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
SGMOSangamo Therapeutics, Inc.2026-06-08 12:05 EST
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
SANASana Biotechnology2026-05-15 13:00 EST
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
ABEOAbeona Therapeutics2026-05-11 12:30 EST
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
SRPTSarepta Therapeutics2026-09-08 12:59 EST
Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-09-04 20:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-09-04 12:50 EST
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
NTLAIntellia2026-09-04 12:00 EST
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
NTLAIntellia2026-08-07 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 12.26 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States